Warning: fopen(/home/virtual/colon/journal/upload/ip_log/ip_log_2024-12.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 95 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 96
Department of Surgery, Chungnam National University Hospital, Daejeon, Korea
Copyright © 2021 The Korean Society of Coloproctology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
CONFLICT OF INTEREST
No conflicts of interest relevant to this study were reported.
Variable | No. of patient |
5-yr DFS |
5-yr OS |
||
---|---|---|---|---|---|
Rate (%) | P-value | Rate (%) | P-value | ||
Sex | 0.538 | 0.902 | |||
Male | 100 | 88.1 | 94.5 | ||
Female | 60 | 91.5 | 93.2 | ||
Age (yr) | 0.438 | 0.117 | |||
< 75 | 136 | 90.0 | 95.4 | ||
≥ 75 | 24 | 86.5 | 83.7 | ||
ASA PS classification | 0.639 | 0.806 | |||
I, II | 143 | 89.0 | 94.1 | ||
III–V | 17 | 93.8 | 92.9 | ||
Sidedness | 0.024 | 0.019 | |||
Right | 51 | 97.8 | 100 | ||
Left | 109 | 85.6 | 91.2 | ||
Tumor complication | 0.661 | 0.268 | |||
No | 104 | 90.0 | 92.9 | ||
Yes | 39 | 85.9 | 100a | ||
CEA level (ng/mL) | < 0.001 | 0.002 | |||
< 5 | 137 | 94.9 | 97.9 | ||
≥5 | 23 | 72.2 | 83.2 | ||
Tumor size (cm) | 0.229 | 0.201 | |||
<5 | 77 | 86.2 | 92.9 | ||
≥5 | 83 | 92.3 | 94.9 | ||
No. of retrieved LN | 0.098 | 0.316 | |||
< 12 | 34 | 80.8 | 90.2 | ||
≥ 12 | 126 | 91.7 | 94.9 | ||
Differentiation | 0.559 | 0.560 | |||
Well, moderate | 156 | 89.2 | 93.8 | ||
Poor, mucinous | 4 | 100 | 100 | ||
Lymphovascular invasion | 0.172 | 0.625 | |||
No | 3 | 66.7 | 100 | ||
Yes | 157 | 89.8 | 93.8 | ||
Perineural invasion | 0.838 | 0.954 | |||
No | 64 | 89.8 | 94.9 | ||
Yes | 96 | 89.1 | 93.3 |
Variable | No-AC (n = 67) | AC (n = 160) | P-value |
---|---|---|---|
Sex | 0.045 | ||
Male | 33 (49.3) | 100 (62.5) | |
Female | 34 (50.7) | 60 (37.5) | |
Age (yr) | < 0.001 | ||
< 75 | 42 (62.7) | 136 (85.0) | |
≥ 75 | 25 (37.3) | 24 (15.0) | |
ASA PS classification | 0.010 | ||
I, II | 51 (76.1) | 143 (89.4) | |
III–V | 16 (23.9) | 17 (10.6) | |
Sidedness | 0.197 | ||
Right | 26 (38.8) | 51 (31.9) | |
Left | 41 (61.2) | 109 (68.1) | |
Tumor complication | 0.399 | ||
No | 59 (88.1) | 137 (85.6) | |
Yes | 8 (11.9) | 23 (14.4) | |
CEA level (ng/mL) | 0.564 | ||
< 5 | 43 (72.9) | 104 (72.7) | |
≥5 | 16 (27.1) | 39 (27.3) | |
Tumor size (cm) | 0.337 | ||
<5 | 35 (52.2) | 77 (48.1) | |
≥5 | 32 (47.8) | 83 (51.9) | |
No. of retrieved LN | 0.489 | ||
< 12 | 15 (22.4) | 34 (21.3) | |
≥ 12 | 52 (77.6) | 126 (78.8) | |
Differentiation | 0.182 | ||
Well, moderate | 63 (94.0) | 156 (97.5) | |
Poor, mucinous | 4 (6.0) | 4 (2.5) | |
Lymphovascular invasion | 0.245 | ||
No | 3 (4.5) | 3 (1.9) | |
Yes | 64 (95.5) | 157 (98.1) | |
Perineural invasion | 0.331 | ||
No | 24 (35.8) | 64 (40.0) | |
Yes | 43 (64.2) | 96 (60.0) |
Variable | HR | 95% CI | P-value |
---|---|---|---|
5-yr DFS | |||
Complication | 2.703 | 0.798–9.150 | 0.110 |
No. of retrieved LN | 5.009 | 1.827–13.733 | 0.002 |
Lymphovascular invasion | 0.300 | 0.037–2.464 | 0.263 |
Perineural invasion | 1.771 | 0.654–4.800 | 0.261 |
AC | 1.970 | 0.570–6.806 | 0.284 |
5-yr OS | |||
Complication | 4.050 | 1.166–14.061 | 0.028 |
No. of retrieved LN | 1.612 | 1.512–14.069 | 0.007 |
Perineural invasion | 1.891 | 0.631–5.664 | 0.255 |
AC | 1.456 | 0.408–5.193 | 0.562 |
Variable | No. of patient | 5-yr DFS |
5-yr OS |
||
---|---|---|---|---|---|
Rate (%) | P-value | Rate (%) | P-value | ||
Sex | 0.557 | 0.557 | |||
Male | 33 | 96.7 | 96.6 | ||
Female | 34 | 93.2 | 93.1 | ||
Age (yr) | 0.279 | 0.251 | |||
< 75 | 42 | 97.4 | 97.3 | ||
≥ 75 | 25 | 90.7 | 90.5 | ||
ASA PS classification | 0.625 | 0.559 | |||
I, II | 51 | 95.7 | 95.7 | ||
III–V | 16 | 91.7 | 91.7 | ||
Sidedness | 0.279 | 0.251 | |||
Right | 26 | 90.7 | 90.5 | ||
Left | 41 | 97.4 | 97.3 | ||
Tumor complication | 0.087 | 0.133 | |||
No | 59 | 96.4 | 96.2 | ||
Yes | 8 | 80.0 | 80.0 | ||
CEA level (ng/mL) | 0.387 | 0.381 | |||
< 5 | 43 | 94.7 | 94.6 | ||
≥5 | 16 | 100 | 100 | ||
Tumor size (cm) | 0.088 | 0.089 | |||
<5 | 35 | 90.2 | 90.0 | ||
≥5 | 32 | 100 | 100 | ||
No. of retrieved LN | 0.001 | 0.001 | |||
< 12 | 15 | 78.6 | 78.6 | ||
≥ 12 | 52 | 100 | 100 | ||
Differentiation | 0.687 | 0.638 | |||
Well, moderate | 63 | 94.7 | 94.5 | ||
Poor, mucinous | 4 | 100 | 100 | ||
Lymphovascular invasion | 0.819 | 0.817 | |||
No | 3 | 100 | 100 | ||
Yes | 64 | 94.9 | 94.7 | ||
Perineural invasion | 0.167 | 0.170 | |||
No | 24 | 100 | 100 | ||
Yes | 43 | 91.8 | 91.7 |
Variable | No. of patient | 5-yr DFS |
5-yr OS |
||
---|---|---|---|---|---|
Rate (%) | P-value | Rate (%) | P-value | ||
Sex | 0.538 | 0.902 | |||
Male | 100 | 88.1 | 94.5 | ||
Female | 60 | 91.5 | 93.2 | ||
Age (yr) | 0.438 | 0.117 | |||
< 75 | 136 | 90.0 | 95.4 | ||
≥ 75 | 24 | 86.5 | 83.7 | ||
ASA PS classification | 0.639 | 0.806 | |||
I, II | 143 | 89.0 | 94.1 | ||
III–V | 17 | 93.8 | 92.9 | ||
Sidedness | 0.024 | 0.019 | |||
Right | 51 | 97.8 | 100 | ||
Left | 109 | 85.6 | 91.2 | ||
Tumor complication | 0.661 | 0.268 | |||
No | 104 | 90.0 | 92.9 | ||
Yes | 39 | 85.9 | 100 |
||
CEA level (ng/mL) | < 0.001 | 0.002 | |||
< 5 | 137 | 94.9 | 97.9 | ||
≥5 | 23 | 72.2 | 83.2 | ||
Tumor size (cm) | 0.229 | 0.201 | |||
<5 | 77 | 86.2 | 92.9 | ||
≥5 | 83 | 92.3 | 94.9 | ||
No. of retrieved LN | 0.098 | 0.316 | |||
< 12 | 34 | 80.8 | 90.2 | ||
≥ 12 | 126 | 91.7 | 94.9 | ||
Differentiation | 0.559 | 0.560 | |||
Well, moderate | 156 | 89.2 | 93.8 | ||
Poor, mucinous | 4 | 100 | 100 | ||
Lymphovascular invasion | 0.172 | 0.625 | |||
No | 3 | 66.7 | 100 | ||
Yes | 157 | 89.8 | 93.8 | ||
Perineural invasion | 0.838 | 0.954 | |||
No | 64 | 89.8 | 94.9 | ||
Yes | 96 | 89.1 | 93.3 |
Values are presented as number (%). AC, adjuvant chemotherapy; ASA, American Society of Anesthesiologists; PS, physical status; CEA, carcinoembryonic antigen; LN, lymph node.
DFS, disease-free survival; OS, overall survival; HR, hazard ratio; CI, confidential interval; LN, lymph node; AC, adjuvant chemotherapy.
DFS, disease-free survival; OS, overall survival; ASA, American Society of Anesthesiologists; PS, physical status; CEA, carcinoembryonic antigen; LN, lymph node.
DFS, disease-free survival; OS, overall survival; ASA, American Society of Anesthesiologists; PS, physical status; CEA, carcinoembryonic antigen, LN, lymph node. 7-year OS, 59.3%.